Hepatic encephalopathy
MONDO:0001711Hepatic encephalopathy is a syndrome observed in some patients with cirrhosis. It is defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, when other known brain disease has been excluded.Signs and symptomsmay be debilitating, and they can begin mildly and gradually, or occur suddenly and severely. They may includepersonality or moodchanges, intellectual impairment, abnormal movements,a depressed level of consciousness, and other symptoms.There are several theories regarding the exact cause, butdevelopment of the condition isprobablyat least partiallydue to the effect of substances that are toxic to nerve tissue (neurotoxic), which are typically present with liver damage and/or liver disease. Treatment depends upon the severity of mental status changes and upon the certainty of the diagnosis.
Also known as: portal-systemic encephalopathy, Hepatoencephalopathy, encephalopathy, hepatic
38 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Poop pills could clear brain fog in liver disease
Disease control OngoingThis study tests whether transplanting healthy gut bacteria from donors can improve confusion in people with advanced liver disease. Thirty participants will receive either fecal transplant capsules or a placebo. The goal is to see if this approach can safely improve thinking and…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Liver drug study pulled before it even started
Disease control TerminatedThis study aimed to see if the antibiotic rifaximin could help people with liver cirrhosis who have a mild form of brain fog called covert hepatic encephalopathy, along with bacterial overgrowth in the gut. Researchers planned to give 40 patients rifaximin for eight weeks and tes…
Phase: PHASE3 • Sponsor: MetroHealth Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for liver patients: drug may delay brain fog and hospital stays
Disease control OngoingThis Phase 3 study tests whether a special form of the antibiotic rifaximin can delay the first episode of overt hepatic encephalopathy (brain dysfunction) in people with liver cirrhosis who have controlled fluid buildup in the belly. About 466 participants will receive either ri…
Phase: PHASE3 • Sponsor: Bausch Health Americas, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC
-
AI boosts brain scan accuracy in massive new trial
Diagnosis ENROLLING_BY_INVITATIONThis study tests whether an AI tool can help radiologists read brain CT and MRI scans more accurately and quickly. Researchers will compare how well doctors, AI alone, and doctors using AI together can spot abnormalities, urgent findings, and classify diseases. The goal is to red…
Sponsor: Yaou Liu • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
New tool aims to predict brain risks after liver shunt procedure
Knowledge-focused OngoingThis study looks back at medical records of 624 adults with liver cirrhosis who had a procedure called TIPS to relieve pressure in the liver. The goal is to create a simple tool that helps doctors predict which patients are at high risk for a brain complication called hepatic enc…
Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Scientists observe liver disease progression in 24 patients
Knowledge-focused OngoingThis study follows 24 adults with liver cirrhosis who recently had a sudden worsening (decompensation) requiring hospital care. Researchers will track their health over time, including lab results and major events like death or liver transplant. The goal is to better understand t…
Sponsor: Resolution Therapeutics Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
300 volunteers help create medical image bank for science
Knowledge-focused OngoingThis study gathers MRI, CT, and ultrasound images from 300 adults—some healthy, some with kidney or brain disease—to build a collection for future not-for-profit research. No new treatments are being tested; the goal is to make medical images available to scientists for advancing…
Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:28 UTC